PALO ALTO, Calif., March 3 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. today announced that four abstracts have been accepted for presentation at the American College of Cardiology (ACC) Scientific Sessions 2006, taking place in Atlanta, GA from March 11-14, 2006. Accepted abstracts include:
-- Ranolazine Safety and Tolerability During Long-Term Treatment of Stable Angina. Tuesday, March 14, 2006 from 10:00 a.m. to 11:00 a.m. Eastern Time (ET), Hall B1, Georgia World Congress Center. Poster Session # 999-253.
-- Better Ventricular Function and Reduced Necrosis After Myocardial Ischemia/Reperfusion in Rabbits Treated With Ranolazine, an Inhibitor of the Late Sodium Current. Sunday, March 12, 2006 from 2:30 p.m. to 3:30 p.m. ET, Hall B1, Georgia World Congress Center. Poster Session # 927-216.
-- African Americans With Chronic Angina: Risk Factors and Treatment Profiles Compared to Caucasians. Tuesday, March 14, 2006 from 7:15 a.m. to 7:30 a.m. ET, Room B405, Georgia World Congress Center. Oral Abstract # 836-4.
-- Hydrogen Peroxide-Induced Arrhythmogenic Activity and Contractile Dysfunction of Ventricular Myocytes Is Reduced by a Blocker of Late Sodium Current. Sunday, March 12, 2006 from 11:00 a.m. to 12:00 p.m. ET, Hall B1, Georgia World Congress Center. Poster Session # 901-130.
Additional information regarding the ACC Scientific Sessions 2006 can be accessed at http://www.acc.org/2006ann_meeting/home/home.htm
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics’ approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets. Ranexa is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. In addition, CV Therapeutics co-promotes ACEON(R), an ACE inhibitor, for reduction of the risk of cardiovascular mortality or nonfatal myocardial infarction in patients with stable coronary artery disease and treatment of essential hypertension.
CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Regadenoson has not been approved for marketing by any regulatory authorities.
Except for the historical information contained herein, the matters set forth in this press release, including statements as to development, clinical studies, special protocol assessment agreements, regulatory review and approval, and commercialization of products, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, early stage of development; regulatory review and approval of our products; special protocol assessment agreements; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; and other risks detailed from time to time in CV Therapeutics’ SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.
CV Therapeutics, Inc.
CONTACT: Investors: Christopher Chai, Vice President, Treasury andInvestor Relations, +1-650-384-8560, or Media: John Bluth, Senior Director,Corporate Communications, +1-650-384-8850, both of CV Therapeutics, Inc.
Web site: http://www.cvt.com/
